Table 2.
Summary of contraceptive efficacy (Pearl Index and life-table analysis) for nomegestrol acetate/17β-oestradiol (N0MAC/E2) and drospirenone/ethinylestradiol (DRSP/EE) in the overall population and age subgroups.
| NOMAC/E2 | DRSP/EE | |||
|---|---|---|---|---|
| 18-50 years | ≤ 35 years | 18-50 years | ≤ 35 years | |
| N | 1587 | 1315 | 534 | 442 |
| Pearl Index analysis | ||||
| Exposure (woman-years) | 1292.5 | 10576 | 452.8 | 372.4 |
| Pregnancies* | 4 | 4 | 3 | 3 |
| Pearl Index estimate | 0.31 | 0.38 | 0.66 | 0.81 |
| 95% Cl | 0.08, 0.79 | 0.10, 0.97 | 0.14, 1.94 | 0.17, 2.35 |
| Life-table analysis | ||||
| Cumulative pregnancy rate after 1 year (%) | 0.33 | 0.40 | 0.64 | 0.77 |
| 95% Cl | 0.12, 0.87 | 0.15, 1.06 | 0.21, 1.97 | 0.25, 2.39 |
Cl, confidence interval.
*
Pregnancies with conception date from the day of first intake of trial medication up to and including the days of last intake of trial medication extended with a maximum of two days. This Pearl Index was calculated by excluding cycles with condom use from the analysis.